September 15, 2017
Researcher presented at the European Association for the Study of Diabetes 2017 highlighted the significant risk of death caused by hypoglycemia among patients with diabetes.
The findings were part of the DEVOTE trial, a multinational, double-blinded clinical trial that observed the efficacy of Tresiba (insulin degludec; Novo Nordisk).
“Episodes of severe hypoglycaemia are not only distressing for patients and potentially dangerous, they are also associated with an increased risk of death,” Bernard Zinman, MD, of the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, said in a press release. “These results highlight the importance of maintaining lown variability in blood sugar levels and reducing the risk of severe hypoglycaemia when treating people with type 2 diabetes.”
Express Scripts Report Highlights Significant Benefit of Diabetes Adherence
Immunotherapy Shows Promise for Type I Diabetes
The researcher showed that patients with diabetes who experience severe hypoglycemia events have a significantly increased risk for death, with risk increasing four times higher at 15 days after an event and more than doubling at any time after an event. Furthermore, the researchers found that fluctuations in blood sugar levels are also associated with a higher risk of death among those with type 2 diabetes.
Furthermore, the researchers—from Novo Nordisk—concluded that Tresiba would reduce the risk of death by reducing the risk for severe hypoglycemia by 40%—compared to patients on Lantus (insulin glargine U100; Sanofi). Furthermore, Tresiba cut the risk for nocturnal hypoglycemia by 53% compared to Lantus. —David Costill